Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fluzone HD

Vaccine (Peptide vaccine) · Immune activation, directed at influenza A virus hemagglutinin and influenza B virus hemagglutinin · developed by Novavax

Phase 2/3 Most advanced trial (none active)
NVAX Developer
2 Registered trials

What is Fluzone HD?

Fluzone HD is a trivalent inactivated influenza vaccine containing 60 µg per strain of three influenza strains.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
influenza A virus hemagglutinin (antigen), influenza B virus hemagglutinin (antigen)
Mechanism
Immune activation, directed at influenza A virus hemagglutinin and influenza B virus hemagglutinin
Pathways
immune_activation
Therapy area
Infectious disease
Developer
Novavax (NVAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06482359 Phase 2/3 COVID-19 Withdrawn NVAX
NCT03293498 Phase 1/2 Influenza Completed NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19Influenza

More from Novavax

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind Fluzone HD

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.